BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21388661)

  • 1. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.
    Yasmeen A; Beauchamp MC; Piura E; Segal E; Pollak M; Gotlieb WH
    Gynecol Oncol; 2011 Jun; 121(3):492-8. PubMed ID: 21388661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and epithelial ovarian cancer therapeutics.
    Patel S; Kumar L; Singh N
    Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative and apoptotic effects of zinc-citrate compound (CIZAR(R)) on human epithelial ovarian cancer cell line, OVCAR-3.
    Bae SN; Lee YS; Kim MY; Kim JD; Park LO
    Gynecol Oncol; 2006 Oct; 103(1):127-36. PubMed ID: 16624386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells.
    Patel S; Singh N; Kumar L
    Asian Pac J Cancer Prev; 2015; 16(16):6973-9. PubMed ID: 26514477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
    Gotlieb WH; Saumet J; Beauchamp MC; Gu J; Lau S; Pollak MN; Bruchim I
    Gynecol Oncol; 2008 Aug; 110(2):246-50. PubMed ID: 18495226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
    Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
    Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3.
    Shirali S; Aghaei M; Shabani M; Fathi M; Sohrabi M; Moeinifard M
    Tumour Biol; 2013 Apr; 34(2):1085-95. PubMed ID: 23345014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Thymoquinone on Apoptosis of SK-OV-3 Ovarian Cancer Cell by Regulation of Bcl-2 and Bax.
    Liu X; Dong J; Cai W; Pan Y; Li R; Li B
    Int J Gynecol Cancer; 2017 Oct; 27(8):1596-1601. PubMed ID: 28692636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.
    Villedieu M; Briand M; Duval M; Héron JF; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 May; 105(2):373-84. PubMed ID: 17276501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.
    Dai Y; Jin S; Li X; Wang D
    Oncotarget; 2017 Jan; 8(1):1354-1368. PubMed ID: 27935869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
    Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
    Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
    Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
    Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
    Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
    Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
    Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Lee S; Choi EJ; Jin C; Kim DH
    Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.